Skip to main navigation Skip to search Skip to main content

Is the generalizability of a developed artificial intelligence algorithm for COVID-19 on chest CT sufficient for clinical use? Results from the International Consortium for COVID-19 Imaging AI (ICOVAI)

  • Laurens Topff*
  • , Kevin B.W. Groot Lipman
  • , the ICOVAI, International Consortium for COVID-19 Imaging AI
  • , Frederic Guffens
  • , Rianne Wittenberg
  • , Annemarieke Bartels-Rutten
  • , Gerben van Veenendaal
  • , Mirco Hess
  • , Kay Lamerigts
  • , Joris Wakkie
  • , Erik Ranschaert
  • , Stefano Trebeschi
  • , Jacob J. Visser
  • , Regina G.H. Beets-Tan
  • *Corresponding author for this work
  • Netherlands Cancer Institute
  • Maastricht University
  • University Hospitals Leuven
  • Aidence
  • St. Nikolaus Hospital
  • Ghent University
  • University of Southern Denmark

Research output: Contribution to journalArticleAcademicpeer-review

9 Citations (Scopus)
72 Downloads (Pure)

Abstract

Objectives: Only few published artificial intelligence (AI) studies for COVID-19 imaging have been externally validated. Assessing the generalizability of developed models is essential, especially when considering clinical implementation. We report the development of the International Consortium for COVID-19 Imaging AI (ICOVAI) model and perform independent external validation. Methods: The ICOVAI model was developed using multicenter data (n = 1286 CT scans) to quantify disease extent and assess COVID-19 likelihood using the COVID-19 Reporting and Data System (CO-RADS). A ResUNet model was modified to automatically delineate lung contours and infectious lung opacities on CT scans, after which a random forest predicted the CO-RADS score. After internal testing, the model was externally validated on a multicenter dataset (n = 400) by independent researchers. CO-RADS classification performance was calculated using linearly weighted Cohen’s kappa and segmentation performance using Dice Similarity Coefficient (DSC). Results: Regarding internal versus external testing, segmentation performance of lung contours was equally excellent (DSC = 0.97 vs. DSC = 0.97, p = 0.97). Lung opacities segmentation performance was adequate internally (DSC = 0.76), but significantly worse on external validation (DSC = 0.59, p < 0.0001). For CO-RADS classification, agreement with radiologists on the internal set was substantial (kappa = 0.78), but significantly lower on the external set (kappa = 0.62, p < 0.0001). Conclusion: In this multicenter study, a model developed for CO-RADS score prediction and quantification of COVID-19 disease extent was found to have a significant reduction in performance on independent external validation versus internal testing. The limited reproducibility of the model restricted its potential for clinical use. The study demonstrates the importance of independent external validation of AI models. Key Points: • The ICOVAI model for prediction of CO-RADS and quantification of disease extent on chest CT of COVID-19 patients was developed using a large sample of multicenter data. • There was substantial performance on internal testing; however, performance was significantly reduced on external validation, performed by independent researchers. The limited generalizability of the model restricts its potential for clinical use. • Results of AI models for COVID-19 imaging on internal tests may not generalize well to external data, demonstrating the importance of independent external validation.

Original languageEnglish
Pages (from-to)4249-4258
Number of pages10
JournalEuropean Radiology
Volume33
Issue number6
Early online date18 Jan 2023
DOIs
Publication statusPublished - Jun 2023

Bibliographical note

Funding Information:
The study has received funding by the Horizon 2020 framework programme of the European Union under grant agreement no. 961522.

Funding Information:
We would like to thank participating hospitals of the ICOVAI consortium. Moreover, we are thankful to the Imaging COVID-19 AI group to provide the dataset to perform the external validation of the ICOVAI model. The International Consortium for COVID-19 Imaging AI (ICOVAI) Albert Schweitzer Hospital, Dordrecht, The Netherlands; Department of Radiology, Deventer Hospital, Deventer, the Netherlands; Department of Radiology, Tergooi Hospital, The Netherlands; Amsterdam University Medical Center, Amsterdam, The Netherlands; Julien Guiot , Department of Pneumology, University Hospital of Liège, Liège, Belgium; Annemiek Snoeckx , Antwerp University Hospital, Antwerp, Belgium, and Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium; Peter Kint , Department of Radiology, Amphia Hospital, Breda, The Netherlands; Lieven Van Hoe , Department of Radiology, OLV Hospital, Aalst, Belgium; Carlo Cosimo Quattrocchi , Departmental Faculty of Medicine and Surgery, Diagnostic Imaging and Interventional Radiology, Università Campus Bio-Medico di Roma, Rome, Italy; Dennis Dieckens , Albert Schweitzer Hospital, Dordrecht, The Netherlands; Samir Lounis , Imapole Lyon-Villeurbanne, France; Eric Schulze , Lifetrack Medical Systems, Singapore; Arnout Eric-bart Sjer , Medical Clinic Velsen, The Netherlands; Niels van Vucht , University College London Hospital, United Kingdom; Jeroen A.W. Tielbeek , Department of Radiology, Spaarne Gasthuis Haarlem / Hoofddorp, The Netherlands; Frank Raat , Laurentius Hospital Roermond, The Netherlands; Daniël Eijspaart , Red Cross Hospital, The Netherlands; Ausami Abbas , University Hospital Southampton, United Kingdom.

Publisher Copyright:
© 2023, The Author(s).

Fingerprint

Dive into the research topics of 'Is the generalizability of a developed artificial intelligence algorithm for COVID-19 on chest CT sufficient for clinical use? Results from the International Consortium for COVID-19 Imaging AI (ICOVAI)'. Together they form a unique fingerprint.

Cite this